UroGen Pharma Ltd. Investment Income, Interest
UroGen Pharma Ltd. (URGN) reported Investment Income, Interest of $946.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-08-05
- UroGen Pharma Ltd. investment income, interest for the quarter ending 2026-06-30 was $946.00K, a 43.59% decline year-over-year.
- UroGen Pharma Ltd. investment income, interest for the quarter ending 2026-03-31 was $931.00K, a 57.76% decline year-over-year.
- UroGen Pharma Ltd. investment income, interest for the quarter ending 2025-12-31 was $908.00K, a 67.71% decline year-over-year.
- UroGen Pharma Ltd. investment income, interest for the quarter ending 2025-09-30 was $1.18M, a 57.34% decline year-over-year.
- UroGen Pharma Ltd. investment income, interest for fiscal 2025 was $5.96M, a 32.99% decline from fiscal 2024.
- UroGen Pharma Ltd. investment income, interest for fiscal 2024 was $8.90M, a 237.03% increase from fiscal 2023.
- UroGen Pharma Ltd. investment income, interest for fiscal 2023 was $2.64M, a 181.56% increase from fiscal 2022.
- UroGen Pharma Ltd. investment income, interest for fiscal 2022 was $938.00K, a 156.99% increase from fiscal 2021.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 3 month as first filed | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $946.00K 10-Q · filed 2026-08-05 | $1.88M 10-Q · filed 2026-08-05 | $2.79M derived: sum of 3 quarters · filed 2026-08-05 | $3.96M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2026-03-31 | $931.00K 10-Q · filed 2026-05-06 | $1.84M derived: sum of 2 quarters · filed 2026-05-06 | $3.02M derived: sum of 3 quarters · filed 2026-05-06 | $4.69M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-12-31 | $908.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $2.08M derived: sum of 2 quarters · filed 2026-03-02 | $3.76M derived: sum of 3 quarters · filed 2026-08-05 | $5.96M 10-K · filed 2026-03-02 | |
| 2025-09-30 | $1.18M 10-Q · filed 2025-11-06 | $2.85M derived: sum of 2 quarters · filed 2026-08-05 | $5.06M 10-Q · filed 2025-11-06 | $7.87M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-06-30 | $1.68M 10-Q · filed 2026-08-05 | $3.88M 10-Q · filed 2026-08-05 | $6.69M derived: sum of 3 quarters · filed 2026-08-05 | $9.45M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-03-31 | $2.20M 10-Q · filed 2026-05-06 | $5.02M derived: sum of 2 quarters · filed 2026-05-06 | $7.77M derived: sum of 3 quarters · filed 2026-05-06 | $9.31M derived: sum of 4 quarters · filed 2026-05-06 | |
| 2024-12-31 | $2.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $5.57M derived: sum of 2 quarters · filed 2026-03-02 | $7.10M derived: sum of 3 quarters · filed 2026-03-02 | $8.90M 10-K · filed 2026-03-02 | |
| 2024-09-30 | $2.76M 10-Q · filed 2025-11-06 | $4.29M derived: sum of 2 quarters · filed 2025-11-06 | $6.09M 10-Q · filed 2025-11-06 | $6.82M derived: sum of 4 quarters · filed 2025-11-06 | |
| 2024-06-30 | $1.53M 10-Q · filed 2025-08-07 | $1.72M 10-Q · filed 2024-08-13 | $3.33M 10-Q · filed 2025-08-07 | $4.06M derived: sum of 3 quarters · filed 2025-08-07 | $4.89M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $1.80M 10-Q · filed 2025-05-12 | $2.52M derived: sum of 2 quarters · filed 2025-05-12 | $3.36M derived: sum of 3 quarters · filed 2025-05-12 | $3.79M derived: sum of 4 quarters · filed 2025-05-12 | |
| 2023-12-31 | $726.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $1.56M derived: sum of 2 quarters · filed 2025-03-10 | $2.00M derived: sum of 3 quarters · filed 2025-03-10 | $2.64M 10-K · filed 2025-03-10 | |
| 2023-09-30 | $835.00K 10-Q · filed 2024-11-06 | $1.27M derived: sum of 2 quarters · filed 2024-11-06 | $1.92M 10-Q · filed 2024-11-06 | $2.38M derived: sum of 4 quarters · filed 2024-11-06 | |
| 2023-06-30 | $435.00K 10-Q · filed 2024-08-13 | $1.08M 10-Q · filed 2024-08-13 | $1.55M derived: sum of 3 quarters · filed 2024-08-13 | $1.99M derived: sum of 4 quarters · filed 2024-08-13 | |
| 2023-03-31 | $645.00K 10-Q · filed 2024-05-13 | $1.11M derived: sum of 2 quarters · filed 2024-05-13 | $1.55M derived: sum of 3 quarters · filed 2024-05-13 | $1.58M derived: sum of 4 quarters · filed 2024-05-13 | |
| 2022-12-31 | $469.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $910.00K derived: sum of 2 quarters · filed 2024-03-14 | $936.00K derived: sum of 3 quarters · filed 2024-03-14 | $938.00K 10-K · filed 2024-03-14 | |
| 2022-09-30 | $441.00K 10-Q · filed 2023-11-14 | $467.00K derived: sum of 2 quarters · filed 2023-11-14 | $469.00K 10-Q · filed 2023-11-14 | $489.00K derived: sum of 4 quarters · filed 2023-11-14 | |
| 2022-06-30 | $26.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $28.00K 10-Q · filed 2023-08-10 | $48.00K derived: sum of 3 quarters · filed 2023-08-10 | $121.00K derived: sum of 4 quarters · filed 2023-08-10 | |
| 2022-03-31 | $2.00K 10-Q · filed 2023-05-11 | $22.00K derived: sum of 2 quarters · filed 2023-05-11 | $95.00K derived: sum of 3 quarters · filed 2023-05-11 | $200.00K derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | $20.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | $93.00K derived: sum of 2 quarters · filed 2023-03-24 | $198.00K derived: sum of 3 quarters · filed 2023-03-24 | $365.00K 10-K · filed 2023-03-24 | |
| 2021-09-30 | $73.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $178.00K derived: sum of 2 quarters · filed 2022-11-10 | $345.00K 10-Q · filed 2022-11-10 | $612.00K derived: sum of 4 quarters · filed 2022-11-10 | |
| 2021-06-30 | $105.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $272.00K 10-Q · filed 2022-08-11 | $539.00K derived: sum of 3 quarters · filed 2022-08-11 | $927.00K derived: sum of 4 quarters · filed 2022-08-11 | |
| 2021-03-31 | $167.00K 10-Q · filed 2022-05-10 | $434.00K derived: sum of 2 quarters · filed 2022-05-10 | $822.00K derived: sum of 3 quarters · filed 2022-05-10 | $1.34M derived: sum of 4 quarters · filed 2022-05-10 | |
| 2020-12-31 | $267.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $655.00K derived: sum of 2 quarters · filed 2022-03-21 | $1.18M derived: sum of 3 quarters · filed 2022-03-21 | $1.99M 10-K · filed 2022-03-21 | |
| 2020-09-30 | $388.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $908.00K derived: sum of 2 quarters · filed 2021-11-15 | $1.72M 10-Q · filed 2021-11-15 | $2.73M derived: sum of 4 quarters · filed 2021-11-15 | |
| 2020-06-30 | $520.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $1.33M 10-Q · filed 2021-08-04 | $2.34M derived: sum of 3 quarters · filed 2021-08-04 | $3.59M derived: sum of 4 quarters · filed 2021-08-04 | |
| 2020-03-31 | $811.00K 10-Q · filed 2021-05-13 | $1.82M derived: sum of 2 quarters · filed 2021-05-13 | $3.07M derived: sum of 3 quarters · filed 2021-05-13 | $4.42M derived: sum of 4 quarters · filed 2021-05-13 | |
| 2019-12-31 | $1.01M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | $2.26M derived: sum of 2 quarters · filed 2021-03-18 | $3.61M derived: sum of 3 quarters · filed 2021-03-18 | $4.62M 10-K · filed 2021-03-18 | |
| 2019-09-30 | $1.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $2.60M derived: sum of 2 quarters · filed 2020-11-09 | $3.61M 10-Q · filed 2020-11-09 | ||
| 2019-06-30 | $1.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $2.35M 10-Q · filed 2020-08-10 | |||
| 2019-03-31 | $1.01M 10-Q · filed 2020-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |